BioCentury
ARTICLE | Company News

Biogen Idec, Isis Pharmaceuticals deal

December 17, 2012 8:00 AM UTC

Isis granted Biogen Idec an exclusive, worldwide option to develop and commercialize antisense candidates against three undisclosed targets to treat neurological or neuromuscular disorders. Isis, which is responsible for discovery and development through the first Phase II trial for each of the programs, will receive a $30 million upfront payment and is eligible for "substantial" development milestones prior to the exercise of the options. Isis is also eligible for up to $200 million in a license fee and regulatory milestones per program, plus double-digit royalties. Biogen Idec has through completion of Phase II testing to exercise its option to license a candidate from each of the three programs. ...